ClinicalTrials.gg
CompletedNCT03127644Updated May 20, 2019Results posted

ZS Ph2/3 Dose-response Study in Japan

A Phase 2/3 interventional study of Sodium Zirconium Cyclosilicate (ZS) 5g and Sodium Zirconium Cyclosilicate (ZS) 10g in Hyperkalemia, sponsored by AstraZeneca. Completed at 25 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-05-20.

Sponsored by AstraZeneca · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
103
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 27 studies testing sodium zirconium cyclosilicate in Hyperkalemia — 3 open to participants now, 4 under way, none of them phase 3. sodium zirconium cyclosilicate · Hyperkalemia.

Enrollment
17th of 27
103 · median 120
Started
2017
with 3 others
Phase 2/3
Only one
of the 27
Registered
5th of 27
by date
Lead sponsor
16 of 27
AstraZeneca

Among the 27 studies testing sodium zirconium cyclosilicate in Hyperkalemia, this one is the 17th largest by enrollment, is one of 4 that started in 2017, is the only one in phase 2/3, and was the 5th registered.

Hyperkalemia

134 studies on the registry are indexed under Hyperkalemia; 26 are open to participants now.

Browse Hyperkalemia studies →

Open to participants now

3 of the 27 studies testing sodium zirconium cyclosilicate in Hyperkalemia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sodium zirconium cyclosilicate

sodium zirconium cyclosilicate: first FDA approval 2018 (LOKELMA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 16 Hyperkalemia studies recruiting now, 11 (69%) set no upper age limit and 2 (13%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing sodium zirconium cyclosilicate in Hyperkalemia, or all of them as a file.
02

Study summary

To assess efficacy of 5 g three times daily (TID) and 10 g TID ZS versus placebo in Japanese patients with hyperkalemia (serum potassium [S-K] ≥ 5.1 mmol/L and ≤ 6.5 mmol/L).

Read the detailed description

Patients not receiving any therapy for hyperkalemia and with 2 consecutive i-STAT potassium values of ≥ 5.1 mmol/L and ≤ 6.5 mmol/L will be enrolled and randomized 1:1:1 to receive ZS 5 g, ZS 10 g, or placebo TID for 48 hours.

Throughout the study most potassium values will be measured at fasting before taking study drug. Nothing should be taken by mouth except water, coffee or tea, with or without milk and/or sugar, and essential medications, prior to the blood collection for a minimum of 8 hours. Potassium level should be determined by both i-STAT and the Central Laboratory on all occasions. Treatment decisions (eg, stopping rules) will be made based on i-STAT potassium values, as these provide clinical sites with a real-time measurement. Statistical analyses on the study data will in principle be based on S-K values as measured by the central laboratory.

Safety and tolerability will be assessed on an ongoing basis. Standard study assessments including blood potassium, clinical chemistry (including calcium, magnesium, sodium, phosphate, creatinine, bicarbonate, and blood urea nitrogen [BUN]) and hematology parameters, urinalysis, vital signs, physical examinations, and electrocardiograms (ECGs) will be assessed during the study at the time points specified in the assessments schedule. All women of childbearing potential will have a urine pregnancy test prior to enrollment and at their End of Study (EOS) visit.

Stopping rules will be implemented to ensure subjects discontinue the study treatment and receive alternative therapy in case of significant hyperkalemia, hypokalemia, or significant cardiac arrhythmias.

03

Conditions studied

  • Hyperkalemia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of prior to any study specific procedures.
  • Patients aged ≥18. For patients aged \<20 years, a written informed consent should be obtained from the patient and his or her legally acceptable representative.
  • Two consecutive i-STAT potassium values, measured 60 (± 10) minutes apart, both values should be ≥ 5.1 mmol/L and ≤ 6.5 mmol/L and measured within 1 day before the first dose of study drug on Study Day 1.
  • Ability to have repeated blood draws or effective venous catheterization.
  • Female patients must be 1 year , surgically sterile, or using an acceptable method of (an acceptable method of contraception is defined as a barrier method in conjunction with a spermicide) for the duration of the study (from the time they sign consent) and for 3 months after the last dose of ZS/matching placebo to prevent pregnancy. In addition, oral contraceptives, approved contraceptive implant, long-term injectable contraception, intrauterine device, or tubal ligation are allowed. Oral contraception alone is not acceptable; additional barrier methods in conjunction with spermicide must be used.

Exclusion criteria

Exclusion Criteria:

  • Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)
  • Cause or symptoms of pseudohyperkalemia, such as

    1. hemolyzed blood specimen due to excessive fist clenching to make veins prominent
    2. hemolyzed blood specimen due to difficult or traumatic venepuncture
    3. history of severe leukocytosis or thrombocytosis
  • Patients treated with lactulose, rifaximin, or other non-absorbed antibiotics for hyperammonemia within 7 days prior to first dose of study drug on Study Day 1
  • Patients treated with resins (such as sevelamer hydrochloride, sodium polystyrene sulfonate [SPS; e.g. Kayexalate®] or calcium polystyrene sulfonate [CPS]), calcium acetate, calcium carbonate, or lanthanum carbonate, within 7 days prior to the first dose of study drug
  • Patients with a of less than 3 months
  • Patients who are severely physically or mentally incapacitated and who, in the opinion of investigator, are unable to perform the patients' tasks associated with the protocol
  • Female patients who are pregnant, lactating, or planning to become pregnant
  • Patients who have an active or history of diabetic ketoacidosis
  • Presence of any condition which, in the opinion of the investigator, places the patient at undue risk or potentially jeopardizes the quality of the data to be generated
  • Known or previous anaphylaxis to ZS or to components thereof
  • Treatment with a drug or device within the last 30 days that has not received regulatory approval at the time of study entry
  • Patients with cardiac arrhythmias that require immediate treatment
  • Patients on dialysis
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
103 participants (actual)

Study arms

  • Experimental
    Sodium Zirconium Cyclosilicate (ZS) 5g

    Suspension administered 5g orally three times daily for 48 hours.

    Drug: Sodium Zirconium Cyclosilicate (ZS) 5g

  • Experimental
    Sodium Zirconium Cyclosilicate (ZS) 10g

    Suspension administered 10g orally three times daily for 48 hours.

    Drug: Sodium Zirconium Cyclosilicate (ZS) 10g

  • Placebo comparator
    Placebo

    Placebo suspension administered orally placebo three times daily for 48 hours.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Exponential Rate of Change in Serum Potassium (S-K) Values During the Initial 48 Hours of Study Drug Treatment

    Blood samples for determination of potassium were collected pre-dose, and at 1, 2, and 4 hours post Dose 1 on Day 1. An additional sample was collected at 90 minutes post Dose 2 on Day 1 if i-STAT potassium values at the 4-hour post Dose 1 time point was ≥ 6.1 or \<4.0 mmol/L. On Day 2 samples were analysed pre-dose, and 1 and 4 hours post Dose 1. S-K levels were analysed at the Central Laboratory. Natural logarithm of S-K from 0 to 48 hours post dose are modelled by the random coefficients model including fixed effects of intercept, time, time x treatment and patient-level random effects for time and intercept. Exponential rate of change refers to the slope estimate from the random coefficients model.

    Time frame: From 0 to 48 hours.

Secondary outcomes

  1. Percentage of Patients Who Achieved Normokalaemia at 48 Hours

    The percentage of patients who achieved normokalaemia (normalisation of S-K values to between 3.5 mmol/L and 5.0 mmol/L, inclusive) at 48 hours after start of dosing was determined. Patients with missing S-K values at 48 hours were regarded as not normokalaemic.

    Time frame: At 48 hours.

  2. Exponential Rate of Change in S-K Values During the Initial 24 Hours of Study Drug Treatment

    Blood samples for determination of potassium were collected pre-dose, and at 1, 2, and 4 hours post Dose 1 on Day 1. An additional sample was collected at 90 minutes post Dose 2 on Day 1 if i-STAT potassium values at the 4-hour post Dose 1 time point was ≥ 6.1 or \<4.0 mmol/L. On Day 2 samples were analysed pre-dose, and 1 and 4 hours post Dose 1. S-K levels were analysed at the Central Laboratory. Natural logarithm of S-K from 0 to 24 hours post dose are modelled by the random coefficients model including fixed effects of intercept, time, time x treatment and patient-level random effects for time and intercept. Exponential rate of change refers to the slope estimate from the random coefficients model.

    Time frame: From 0 to 24 hours.

  3. Percentage of Patients Who Achieved Normokalaemia at 24 Hours

    The percentage of patients who achieved normokalaemia (normalisation of S-K values to between 3.5 mmol/L and 5.0 mmol/L, inclusive) at 24 hours after start of dosing was determined. Patients with missing S-K values at 24 hours were regarded as not normokalaemic.

    Time frame: At 24 hours.

  4. Percentage of Patients Who Achieved Normokalaemia at Each Scheduled Potassium Assessment Time Point

    The percentage of patients who achieved normokalaemia (normalisation of S-K values to between 3.5 mmol/L and 5.0 mmol/L, inclusive) at each each scheduled potassium assessment time point after the start of dosing was determined. Patients with missing S-K values were regarded as not normokalaemic.

    Time frame: From baseline to end of study (9 days).

  5. Mean Change From Baseline in S-K Values at All Measured Time Intervals

    Blood samples for determination of potassium were collected pre-dose, and at 1, 2, and 4 hours post Dose 1 on Day 1. An additional sample was collected at 90 minutes post Dose 2 on Day 1 if i-STAT potassium values at the 4-hour post Dose 1 time point was ≥ 6.1 or \<4.0 mmol/L. On Day 2 samples were analysed pre-dose, and 1 and 4 hours post Dose 1. S-K levels were analysed locally using i-STAT devices, and at the Central Laboratory. S-K values measured at each time point and end of study visit were recorded and mean change from baseline is displayed.

    Time frame: From baseline to end of study (9 days).

  6. Mean Percent Change From Baseline in S-K Values at All Measured Time Intervals

    Blood samples for determination of potassium were collected pre-dose, and at 1, 2, and 4 hours post Dose 1 on Day 1. An additional sample was collected at 90 minutes post Dose 2 on Day 1 if i-STAT potassium values at the 4-hour post Dose 1 time point was ≥ 6.1 or \<4.0 mmol/L. On Day 2 samples were analysed pre-dose, and 1 and 4 hours post Dose 1. S-K levels were analysed locally using i-STAT devices, and at the Central Laboratory. S-K values measured at each time point and end of study visit were recorded and mean percent change from baseline is displayed.

    Time frame: From baseline to end of study (9 days).

  7. Time to Normalisation in S-K Values

    The distribution of time to normalisation of S-K values (defined as S-K values between 3.5 mmol/L and 5.0 mmol/L, inclusive) was measured. A patient who reached at least one S-K within normal range was counted as an event regardless of S-K value after that time point. Patients who did not achieve normokalaemia within 48 hours were censored.

    Time frame: From 0 to 48 hours.

  8. Time to a Decrease in S-K Levels of 0.5 mmol/L

    The median time (hours) for S-K values to decrease by 0.5 mmol/L was measured.

    Time frame: From 0 to 48 hours.

07

Results

Posted May 20, 2019

Participant flow

Patients not receiving any therapy for hyperkalaemia and with 2 consecutive potassium values of ≥ 5.1 millimoles/litre (mmol/L) and ≤ 6.5 mmol/L (as measured by i-STAT, a portable blood analyser) were enrolled into 24 study sites in Japan from June 2017 to February 2018.

Participant flow — Overall Study
MilestoneZS 5 g TIDZS 10 g TIDPlacebo TID
Started343633
Completed343631
Not completed002
Withdrew: Study-specific withdrawal criteria002

Outcome measures

PrimaryExponential Rate of Change in Serum Potassium (S-K) Values During the Initial 48 Hours of Study Drug Treatment

Blood samples for determination of potassium were collected pre-dose, and at 1, 2, and 4 hours post Dose 1 on Day 1. An additional sample was collected at 90 minutes post Dose 2 on Day 1 if i-STAT potassium values at the 4-hour post Dose 1 time point was ≥ 6.1 or \<4.0 mmol/L. On Day 2 samples were analysed pre-dose, and 1 and 4 hours post Dose 1. S-K levels were analysed at the Central Laboratory. Natural logarithm of S-K from 0 to 48 hours post dose are modelled by the random coefficients model including fixed effects of intercept, time, time x treatment and patient-level random effects for time and intercept. Exponential rate of change refers to the slope estimate from the random coefficients model.

Time frame:
From 0 to 48 hours.
Reported as:
Mean · log (mmol/L) / hour
Exponential Rate of Change in Serum Potassium (S-K) Values During the Initial 48 Hours of Study Drug Treatment
log (mmol/L) / hourZS 5 g TIDZS 10 g TIDPlacebo TID
Exponential Rate of Change in Serum Potassium (S-K) Values During the Initial 48 Hours of Study Drug Treatment-0.00273 ± 0.000276-0.00508 ± 0.000269-0.00012 ± 0.000288
Statistical analysis
  • ZS 10 g TID vs Placebo TID · Mixed Models Analysis · p = <0.0001 · Treatment difference in slopes: -0.00496 · 95% CI -0.00571 to -0.00420Negative exponential rate of change relative to placebo indicates more rapid reduction (correction) of S-K.
  • ZS 5 g TID vs Placebo TID · Mixed Models Analysis · p = <0.001 · Treatment difference in slopes: -0.00261 · 95% CI -0.00337 to -0.00185Negative exponential rate of change relative to placebo indicates more rapid reduction (correction) of S-K.
SecondaryPercentage of Patients Who Achieved Normokalaemia at 48 Hours

The percentage of patients who achieved normokalaemia (normalisation of S-K values to between 3.5 mmol/L and 5.0 mmol/L, inclusive) at 48 hours after start of dosing was determined. Patients with missing S-K values at 48 hours were regarded as not normokalaemic.

Time frame:
At 48 hours.
Reported as:
Number · Percentage of Patients
Percentage of Patients Who Achieved Normokalaemia at 48 Hours
Percentage of PatientsZS 5 g TIDZS 10g TIDPlacebo TID
Percentage of Patients Who Achieved Normokalaemia at 48 Hours85.391.715.2
Statistical analysis
  • ZS 5 g TID vs Placebo TID · Regression, Logistic · p = <0.0001 · Odds ratio (or): 46.495 · 95% CI 10.142 to 213.152
  • ZS 10g TID vs Placebo TID · Regression, Logistic · p = <0.0001 · Odds ratio (or): 71.835 · 95% CI 13.497 to 382.337
SecondaryExponential Rate of Change in S-K Values During the Initial 24 Hours of Study Drug Treatment

Blood samples for determination of potassium were collected pre-dose, and at 1, 2, and 4 hours post Dose 1 on Day 1. An additional sample was collected at 90 minutes post Dose 2 on Day 1 if i-STAT potassium values at the 4-hour post Dose 1 time point was ≥ 6.1 or \<4.0 mmol/L. On Day 2 samples were analysed pre-dose, and 1 and 4 hours post Dose 1. S-K levels were analysed at the Central Laboratory. Natural logarithm of S-K from 0 to 24 hours post dose are modelled by the random coefficients model including fixed effects of intercept, time, time x treatment and patient-level random effects for time and intercept. Exponential rate of change refers to the slope estimate from the random coefficients model.

Time frame:
From 0 to 24 hours.
Reported as:
Mean · log (mmol/L) / hour
Exponential Rate of Change in S-K Values During the Initial 24 Hours of Study Drug Treatment
log (mmol/L) / hourZS 5 g TIDZS 10 g TIDPlacebo TID
Exponential Rate of Change in S-K Values During the Initial 24 Hours of Study Drug Treatment-0.00234 ± 0.000468-0.00403 ± 0.000457-0.00002 ± 0.000489
Statistical analysis
  • ZS 5 g TID vs Placebo TID · Mixed Models Analysis · p = 0.0004 · Treatment difference in slopes: -0.00231 · 95% CI -0.00359 to -0.00104Negative exponential rate of change relative to placebo indicates more rapid reduction (correction) of S-K.
  • ZS 10 g TID vs Placebo TID · Mixed Models Analysis · p = <0.0001 · Treatment difference in slopes: -0.00401 · 95% CI -0.00527 to -0.00275Negative exponential rate of change relative to placebo indicates more rapid reduction (correction) of S-K.
SecondaryPercentage of Patients Who Achieved Normokalaemia at 24 Hours

The percentage of patients who achieved normokalaemia (normalisation of S-K values to between 3.5 mmol/L and 5.0 mmol/L, inclusive) at 24 hours after start of dosing was determined. Patients with missing S-K values at 24 hours were regarded as not normokalaemic.

Time frame:
At 24 hours.
Reported as:
Number · Percentage of Patients
Percentage of Patients Who Achieved Normokalaemia at 24 Hours
Percentage of PatientsZS 5 g TIDZS 10g TIDPlacebo TID
Percentage of Patients Who Achieved Normokalaemia at 24 Hours35.383.327.3
Statistical analysis
  • ZS 5 g TID vs Placebo TID · Regression, Logistic · p = 0.6167 · Odds ratio (or): 1.347 · 95% CI 0.419 to 4.329
  • ZS 10g TID vs Placebo TID · Regression, Logistic · p = <0.0001 · Odds ratio (or): 15.334 · 95% CI 4.006 to 58.697
SecondaryPercentage of Patients Who Achieved Normokalaemia at Each Scheduled Potassium Assessment Time Point

The percentage of patients who achieved normokalaemia (normalisation of S-K values to between 3.5 mmol/L and 5.0 mmol/L, inclusive) at each each scheduled potassium assessment time point after the start of dosing was determined. Patients with missing S-K values were regarded as not normokalaemic.

Time frame:
From baseline to end of study (9 days).
Reported as:
Number · Percentage of Patients
Percentage of Patients Who Achieved Normokalaemia at Each Scheduled Potassium Assessment Time Point
Percentage of PatientsZS 5 g TIDZS 10g TIDPlacebo TID
Baseline2.95.60.0
1 hour after first dose29.447.221.2
2 hours after first dose41.258.342.4
4 hours after first dose44.163.942.4
24 hours after first dose35.383.327.3
25 hours after first dose73.597.218.2
28 hours after first dose67.697.236.4
48 hours after first dose85.391.715.2
End of study (Last dose + 7 days)55.961.127.3
SecondaryMean Change From Baseline in S-K Values at All Measured Time Intervals

Blood samples for determination of potassium were collected pre-dose, and at 1, 2, and 4 hours post Dose 1 on Day 1. An additional sample was collected at 90 minutes post Dose 2 on Day 1 if i-STAT potassium values at the 4-hour post Dose 1 time point was ≥ 6.1 or \<4.0 mmol/L. On Day 2 samples were analysed pre-dose, and 1 and 4 hours post Dose 1. S-K levels were analysed locally using i-STAT devices, and at the Central Laboratory. S-K values measured at each time point and end of study visit were recorded and mean change from baseline is displayed.

Time frame:
From baseline to end of study (9 days).
Reported as:
Mean · mmol/L
Mean Change From Baseline in S-K Values at All Measured Time Intervals
mmol/LZS 5 g TIDZS 10g TIDPlacebo TID
1 hour after first dose-0.20 ± 0.34-0.37 ± 0.35-0.13 ± 0.32
2 hours after first dose-0.41 ± 0.28-0.50 ± 0.40-0.33 ± 0.30
4 hours after first dose-0.40 ± 0.32-0.53 ± 0.36-0.43 ± 0.31
24 hours after first dose-0.51 ± 0.30-0.69 ± 0.38-0.22 ± 0.35
25 hours after first dose-0.74 ± 0.31-1.00 ± 0.45-0.27 ± 0.31
28 hours after first dose-0.72 ± 0.35-1.12 ± 0.39-0.41 ± 0.43
48 hours after first dose-0.83 ± 0.31-1.30 ± 0.48-0.24 ± 0.34
End of study (Last dose + 7 days)-0.56 ± 0.38-0.66 ± 0.52-0.20 ± 0.59
SecondaryMean Percent Change From Baseline in S-K Values at All Measured Time Intervals

Blood samples for determination of potassium were collected pre-dose, and at 1, 2, and 4 hours post Dose 1 on Day 1. An additional sample was collected at 90 minutes post Dose 2 on Day 1 if i-STAT potassium values at the 4-hour post Dose 1 time point was ≥ 6.1 or \<4.0 mmol/L. On Day 2 samples were analysed pre-dose, and 1 and 4 hours post Dose 1. S-K levels were analysed locally using i-STAT devices, and at the Central Laboratory. S-K values measured at each time point and end of study visit were recorded and mean percent change from baseline is displayed.

Time frame:
From baseline to end of study (9 days).
Reported as:
Mean · Percent change
Mean Percent Change From Baseline in S-K Values at All Measured Time Intervals
Percent changeZS 5 g TIDZS 10g TIDPlacebo TID
1 hour after first dose-3.61 ± 6.28-6.72 ± 6.29-2.32 ± 5.60
2 hours after first dose-7.46 ± 5.04-9.07 ± 6.88-6.06 ± 5.40
4 hours after first dose-7.08 ± 5.65-9.70 ± 6.53-7.77 ± 5.62
24 hours after first dose-8.98 ± 5.33-12.51 ± 6.30-3.81 ± 6.24
25 hours after first dose-13.20 ± 5.42-18.06 ± 7.05-4.77 ± 5.66
28 hours after first dose-12.90 ± 6.10-20.47 ± 6.38-7.21 ± 7.61
48 hours after first dose-14.81 ± 5.08-23.64 ± 8.27-4.06 ± 5.93
End of study (Last dose + 7 days)-9.85 ± 6.51-11.89 ± 9.07-3.15 ± 9.99
SecondaryTime to Normalisation in S-K Values

The distribution of time to normalisation of S-K values (defined as S-K values between 3.5 mmol/L and 5.0 mmol/L, inclusive) was measured. A patient who reached at least one S-K within normal range was counted as an event regardless of S-K value after that time point. Patients who did not achieve normokalaemia within 48 hours were censored.

Time frame:
From 0 to 48 hours.
Reported as:
Median · Hours
Time to Normalisation in S-K Values
HoursZS 5g TIDZS 10g TIDPlacebo TID
Time to Normalisation in S-K Values3.883 (1.767 to 23.083)1.758 (1.000 to 3.967)3.867 (1.917 to NA)
Statistical analysis
  • ZS 5g TID vs Placebo TID · Log Rank · p = 0.0586 (Nominal p value)
  • ZS 10g TID vs Placebo TID · Log Rank · p = 0.0006 (Nominal p value)
SecondaryTime to a Decrease in S-K Levels of 0.5 mmol/L

The median time (hours) for S-K values to decrease by 0.5 mmol/L was measured.

Time frame:
From 0 to 48 hours.
Reported as:
Median · Hours
Time to a Decrease in S-K Levels of 0.5 mmol/L
HoursZS 5g TIDZS 10g TIDPlacebo TID
Time to a Decrease in S-K Levels of 0.5 mmol/L3.883 (1.933 to 19.767)2.892 (1.083 to 4.100)4.050 (1.983 to 23.667)
Statistical analysis
  • ZS 5g TID vs Placebo TID · Log Rank · p = 0.0250 (Nominal p value)
  • ZS 10g TID vs Placebo TID · Log Rank · p = 0.0064 (Nominal p value)

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) were reported from Day 1 to Day 3 inclusive.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ZS 5 g TID0/34 (0%)0/34 (0%)4/34 (11.8%)
ZS 10 g TID0/36 (0%)0/36 (0%)5/36 (13.9%)
Placebo TID0/33 (0%)0/33 (0%)1/33 (3%)
Most frequent other events
Most frequent other events
EventZS 5 g TIDZS 10 g TIDPlacebo TID
Respiratory tract infectionInfections and infestations0/340/361/33
Viral upper respiratory tract infectionInfections and infestations1/340/360/33
Nephrogenic anaemiaBlood and lymphatic system disorders1/340/360/33
ConstipationGastrointestinal disorders1/340/360/33
ThirstGeneral disorders1/340/360/33
HypoglycaemiaMetabolism and nutrition disorders0/341/360/33
Tension headacheNervous system disorders0/341/360/33
TremorNervous system disorders0/341/360/33
Ventricular extrasystolesCardiac disorders0/341/360/33
ErythemaSkin and subcutaneous tissue disorders0/341/360/33

Baseline characteristics

The full analysis set included all patients randomised in the study.

Age, Continuous
Age, Continuous(Years)ZS 5 g TIDZS 10 g TIDPlacebo TIDTotal
Mean72.4 ± 7.971.1 ± 7.676.1 ± 6.873.2 ± 7.7
Age, Customized
Age, Customized(Participants)ZS 5 g TIDZS 10 g TIDPlacebo TIDTotal
<55 years0101
55 to 64 years74112
≥65 years27313290
Sex: Female, Male
Sex: Female, Male(Participants)ZS 5 g TIDZS 10 g TIDPlacebo TIDTotal
Female881026
Male26282377
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ZS 5 g TIDZS 10 g TIDPlacebo TIDTotal
Hispanic or Latino0000
Not Hispanic or Latino343633103
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ZS 5 g TIDZS 10 g TIDPlacebo TIDTotal
American Indian or Alaska Native0000
Asian343633103
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White0000
More than one race0000
Unknown or Not Reported0000
08

Study locations

25 sites
  • Research Site
    Chiba-shi, 260-8712, Japan
  • Research Site
    Chiba-shi, 263-0043, Japan
  • Research Site
    Hanyu-shi, 348-8505, Japan
  • Research Site
    Higashiibaraki-gun, 311-3193, Japan
  • Research Site
    Hitachinaka-shi, 312-0057, Japan
  • Research Site
    Ina-shi, 396-8555, Japan
  • Research Site
    Kagoshima-shi, 892-8580, Japan
  • Research Site
    Kahoku-gun, 920-0293, Japan
  • Research Site
    Kamakura-shi, 247-8533, Japan
  • Research Site
    Kanazawa-shi, 920-8650, Japan
  • Research Site
    Kasugai-shi, 486-8510, Japan
  • Research Site
    Kawachinagano-shi, 586-8521, Japan
  • Research Site
    Kawasaki-shi, 216-8511, Japan
  • Research Site
    Kitakyushu-shi, 802-0001, Japan
  • Research Site
    Koga-shi, 306-0041, Japan
  • Research Site
    Kusatsu-shi, 525-8585, Japan
  • Research Site
    Matsudo-shi, 271-0077, Japan
  • Research Site
    Matsuyama-shi, 791-8026, Japan
  • Research Site
    Nagoya-shi, 457-8511, Japan
  • Research Site
    Naka-shi, 311-0113, Japan
  • Research Site
    Omura-shi, 856-8562, Japan
  • Research Site
    Shimajiri-gun, 901-0493, Japan
  • Research Site
    Shizuoka-shi, 421-0117, Japan
  • Research Site
    Yao-shi, 581-0011, Japan
  • Research Site
    Yotsukaido-shi, 284-0027, Japan
09

References and documents

Publications

  • Kashihara N, Nishio T, Osonoi T, Saka Y, Imasawa T, Ohtake T, Mizuno H, Shibagaki Y, Kim H, Yajima T, Sarai N. Correction of serum potassium with sodium zirconium cyclosilicate in Japanese patients with hyperkalemia: a randomized, dose-response, phase 2/3 study. Clin Exp Nephrol. 2020 Dec;24(12):1144-1153. doi: 10.1007/s10157-020-01937-1. Epub 2020 Aug 10. PubMed 32779057 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2017 to primary completion in Feb 2018, 8 months.

Results were first posted in May 2019, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2017
First posted
Apr 25, 2017
StartActual
Jun 14, 2017
Primary completionActual
Feb 23, 2018
CompletionActual
Feb 23, 2018
Results first posted
May 20, 2019
Last update
May 20, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03127644
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Apr 25, 2017
Start date
Jun 14, 2017
Primary completion
Feb 23, 2018
Completion
Feb 23, 2018
Results posted
May 20, 2019
Last update
May 20, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sodium zirconium cyclosilicate

Start the discussion